Lilly Endowment Files to Sell $344M in LLY Stock Amid Ongoing Dispositions
LLY sits 93% above its 52-week low of $623.78.
Summary
Lilly Endowment, a major shareholder, plans to sell $344 million in Eli Lilly stock, continuing a pattern of large dispositions totaling nearly $1.3 billion in the last three months.
Key Events · Ownership and Investor Activity · LLY
-
Proposed Stock Sale
Lilly Endowment, Inc. intends to sell 305,000 shares of Eli Lilly common stock, valued at approximately $343.9 million.
-
Ongoing Share Dispositions
This filing is part of a larger pattern, with the endowment having sold 1,215,000 shares totaling nearly $1.3 billion over the past three months.
-
Shareholder Activity Near 52-Week Highs
The sales by the major shareholder occur while Eli Lilly's stock is trading near its 52-week high, potentially indicating profit-taking or portfolio rebalancing.
Analysis · LLY · Life Sciences
Lilly Endowment, Inc., a significant shareholder, has filed a Form 144 indicating its intent to sell approximately $344 million worth of Eli Lilly common stock. This proposed sale follows nearly $1.3 billion in sales by the endowment over the past three months, part of a consistent pattern of dispositions. While substantial in absolute dollar terms, these sales represent a small fraction of Eli Lilly's total market capitalization. The sales occur as the stock trades near its 52-week high, suggesting potential profit-taking or portfolio rebalancing by the endowment.
At the time of this filing, LLY was trading at $1,201.23 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,208.18. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.